The artificial intelligence (AI)-enabled software, which has a documented 91 percent sensitivity rate for detecting pediatric fractures, is reportedly the first AI fracture detection modality to receive FDA 510(k) clearance for use in the pediatric population.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the use of BoneView (Gleamer), an artificial intelligence (AI) software that helps detect fractures on X-ray, in patients over two years of age.1
In a recently published study involving 300 pediatric patients, researchers demonstrated a 91.3 percent sensitivity rate and a 90 percent sensitivity rate for fracture detection.2
Christian Allouche, the chief executive officer of Gleamer, called the pediatric clearance a significant advance in the company’s efforts to improve fracture detection and diagnosis through the use of AI.1
Employing deep learning algorithms, the BoneView software analyzes X-rays and highlights regions of interest for suspected fractures that are sent to the radiologist for confirmation, according to Gleamer. The company said BoneView is the only AI fracture detection software to have FDA clearance for use in adults and pediatric patients.
The FDA initially granted BoneView 510(k) clearance in March 2022 for fracture detection in adults.3
Study Assesses Potential of Seven-Minute AI-Enhanced 3T MRI of the Shoulder
February 20th 2025Researchers found that the use of seven-minute threefold parallel imaging-accelerated deep learning 3T MRI had 89 percent sensitivity for supraspinatus-infraspinatus tendon tears and 93 percent sensitivity for superior labral tears.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.